Drugs / Pascoflair
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01047605 | Jan → Mar 2010 | — | Pascoe Pharmazeutische Praeparate GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05049447 Comparator | May → Aug 2015 | anxiety | Pascoe Pharmazeutische Praeparate GmbH | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-12 | Pascoe Pharmazeutische Praeparate GmbH | Pascoflair®: Nicht nur in Deutschland, sondern nun auch in Dänemark und Norwegen titandioxidfrei pascoe.de ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pascoflair | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01047605 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “two herbal medicinal products (Neurapas balance and Pascoflair 425 mg)” NCT01047605 ↗ |